Latest Period
Q4 2025
Security Snapshot
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) Institutional Ownership
CUSIP: 984241109
13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$8.61
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- YMAB
- Shares outstanding
- 45,101,565
- Price per share
- $8.61
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -16,393
- Value change
- -$78,346
- Number of holders
- 0
- Price from insider filings
- $8.61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 984241109.
- 0 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 2 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $78,346 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 0 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 984241109?
CUSIP 984241109 identifies YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 984241109:
Significant Owners of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. | 6.2% | -11% | $13,338,337 | -$1,431,000 | 2,796,297 | -9.7% | Anders Hove | 19 Aug 2025 |
As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB). This represents 0% of the company’s total 45,101,565 outstanding shares.
Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$78,346 | $8.61 | 0 |
| 2025 Q3 | 16,393 | $78,346 | -$125,346,804 | $6.66 | 2 |
| 2025 Q2 | 27,903,915 | $125,848,990 | -$3,989,579 | $4.51 | 96 |
| 2025 Q1 | 28,806,277 | $127,612,664 | -$6,925,835 | $4.43 | 102 |
| 2024 Q4 | 28,798,220 | $225,491,854 | -$942,932 | $7.83 | 111 |
| 2024 Q3 | 25,737,929 | $338,544,539 | +$17,304,991 | $13.15 | 105 |
| 2024 Q2 | 24,348,906 | $294,136,627 | +$14,837,664 | $12.08 | 95 |
| 2024 Q1 | 22,993,565 | $373,875,065 | +$49,054,572 | $16.26 | 94 |
| 2023 Q4 | 20,232,989 | $137,987,136 | +$5,157,820 | $6.82 | 93 |
| 2023 Q3 | 19,680,958 | $107,258,625 | +$812,221 | $5.45 | 98 |
| 2023 Q2 | 19,501,430 | $132,412,962 | +$4,779,033 | $6.79 | 94 |
| 2023 Q1 | 19,046,672 | $95,423,185 | -$1,127,392 | $5.01 | 84 |
| 2022 Q4 | 19,342,439 | $94,388,828 | -$55,189,832 | $4.88 | 90 |
| 2022 Q3 | 23,585,540 | $340,103,128 | -$17,897,969 | $14.42 | 95 |
| 2022 Q2 | 24,763,276 | $374,657,143 | -$7,577,417 | $15.13 | 90 |
| 2022 Q1 | 25,303,485 | $300,604,312 | -$14,876,098 | $11.88 | 87 |
| 2021 Q4 | 25,735,284 | $417,099,601 | -$24,204,070 | $16.21 | 94 |
| 2021 Q3 | 26,245,129 | $749,015,343 | -$2,981,846 | $28.54 | 96 |
| 2021 Q2 | 26,145,321 | $886,898,417 | -$1,159,329 | $33.80 | 99 |
| 2021 Q1 | 26,332,523 | $796,209,961 | +$116,007,549 | $30.24 | 116 |
| 2020 Q4 | 22,809,127 | $1,129,308,254 | +$38,442,838 | $49.51 | 115 |
| 2020 Q3 | 21,437,747 | $823,089,252 | +$3,018,102 | $38.39 | 105 |
| 2020 Q2 | 21,284,113 | $919,504,408 | +$53,403,136 | $43.20 | 108 |
| 2020 Q1 | 20,069,737 | $522,452,562 | +$16,002,866 | $26.10 | 80 |
| 2019 Q4 | 19,404,437 | $606,386,157 | +$184,880,658 | $31.25 | 81 |
| 2019 Q3 | 13,139,685 | $342,418,499 | +$56,540,594 | $26.06 | 65 |
| 2019 Q2 | 10,972,436 | $250,918,214 | +$54,344,617 | $22.87 | 59 |
| 2019 Q1 | 8,480,229 | $222,267,926 | -$3,116,524 | $26.21 | 44 |
| 2018 Q4 | 8,686,033 | $175,686,000 | +$16,927,076 | $20.34 | 42 |
| 2018 Q3 | 7,733,371 | $205,387,000 | +$205,387,000 | $26.56 | 38 |